Jan 29 (Reuters) - Immunitybio Inc IBRX.O:
IMMUNITYBIO ANNOUNCES COLLABORATION WITH BEIGENE ON CONFIRMATORY PHASE 3 TRIAL OF ANKTIVA® AND PD-1 CHECKPOINT INHIBITOR COMBINATION IN NON-SMALL CELL LUNG CANCER
IMMUNITYBIO INC - TO SUBMIT BLA IN 2025 BASED ON QUILT 3.055 DATA
IMMUNITYBIO INC - PATENT FOR ANKTIVA AND CPI COMBINATIONS EXTENDS TO 2035
Source text: ID:nBw6YYSLka
Further company coverage: IBRX.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.